Skip to main content
Figure 5 | BMC Gastroenterology

Figure 5

From: Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients

Figure 5

Biomarkers detect two subgroups of patients in the phase IIa study. Whole blood was collected at screening from 32 patients and PBMC incubated for 48 hrs in the absence or presence of Dexamethasone and/or DIMS0150. The expression levels for (A) IL-6 and (B) CD163 were analysed and the data divided into two groups using arbitrary cut-offs. In case of IL-6, one patient had an outlying IL-6 stimulation (>100 fold) and was removed from the analysis. The P-values between two groups were calculated using unpaired t-test, the P-values inside a group were calculated using paired t-test.

Back to article page